Edition:
United States

Dermira Inc (DERM.OQ)

DERM.OQ on NASDAQ Stock Exchange Global Select Market

24.00USD
20 Nov 2017
Change (% chg)

-- (--)
Prev Close
$24.00
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
121,467
52-wk High
$38.75
52-wk Low
$21.39

Latest Key Developments (Source: Significant Developments)

Dermira posts Q3 loss $4.30/shr, says FDA accepts NDA for glycopyrronium tosylate
Monday, 6 Nov 2017 04:03pm EST 

Nov 6 (Reuters) - Dermira Inc :Dermira reports third quarter 2017 financial results and announces that FDA accepts new drug application for glycopyrronium tosylate for the treatment of patients with primary axillary hyperhidrosis.Dermira Inc - ‍FDA decision on new drug application for glycopyrronium tosylate expected by June 30, 2018​.Dermira Inc - qtrly net loss per share, basic and diluted $4.30 ‍​.Dermira Inc - updating its financial guidance for full year 2017; now expects collaboration and license revenue of approximately $4.3 million for FY​.  Full Article

Dermira and UCB agree to end collaboration agreement for Cimzia
Monday, 6 Nov 2017 04:01pm EST 

Nov 6 (Reuters) - Dermira Inc :Dermira and UCB agree to end collaboration agreement for Cimzia.Dermira Inc - ‍Dermira to transition development and commercialization responsibility for Cimzia (Certolizumab Pegol) in psoriasis back to UCB​.Dermira Inc - ‍collaboration agreement will terminate on February 15, 2018 and companies anticipate completion of transition by such date​.Dermira Inc - ‍pursuant to collaboration agreement, there are no termination or penalty payments required by either party​.Dermira - for repurchase of all product rights, licenses and intellectual property relating to cimzia, ucb will pay to dermira $11.0 million by Nov 13.  Full Article

Dermira completes patient enrollment in two phase 3 trials of olumacostat glasaretil for the treatment of acne vulgaris
Thursday, 5 Oct 2017 08:00am EDT 

Oct 5 (Reuters) - Dermira Inc :Dermira completes patient enrollment in two phase 3 pivotal trials of olumacostat glasaretil for the treatment of acne vulgaris.Dermira Inc - Dermira expects to announce topline efficacy and safety results from CLAREOS-1 and CLAREOS-2 studies in Q1 of 2018.  Full Article

Dermira enters into agreement to license exclusive, worldwide rights to Lebrikizumab
Tuesday, 8 Aug 2017 07:30am EDT 

Aug 8 (Reuters) - Dermira Inc :Dermira enters into agreement to license exclusive, worldwide rights to Lebrikizumab.Dermira Inc - Initiation of a phase 2B clinical study is expected in Q1 of 2018​.Dermira Inc - ‍Plans to develop and commercialize Lebrikizumab, a monoclonal antibody targeting IL-13, for moderate-to-severe Atopic Dermatitis​.Dermira Inc - Under terms of agreement, Dermira will make an initial payment of $80 million to Roche and payments totaling $55 million in 2018.Dermira Inc - Dermira will also be obligated to make additional payments upon achievement of certain milestones.Dermira Inc - Expects to record a charge related to acquisition of in-process research and development for a total of $135 million​.Dermira Inc - ‍Estimates it will incur up to $10 million in operating expenses in 2017 for costs related to transferring Lebrikizumab program to dermira​.Dermira Inc - cash and cash equivalents and investments would be sufficient to meet its anticipated cash requirements into first half of 2019.Dermira Inc - Dermira anticipates that it will spend approximately $200 million to obtain topline results for phase 2B study.  Full Article

Dermira Q2 qtrly ‍net loss per share $0.93​
Monday, 7 Aug 2017 04:05pm EDT 

Aug 7 (Reuters) - Dermira Inc ::Dermira reports second quarter 2017 financial results and provides corporate update.Dermira Inc qtrly ‍net loss per share, basic and diluted, $0.93​.Dermira - ‍as of June 30, co had cash, cash equivalents and short- and long-term investments of $695.9 million and 41.6 million common shares outstanding​.Dermira Inc - ‍reiterates its previously issued financial guidance for full year 2017​.Dermira Inc - ‍for glycopyrronium tosylate, management anticipates submission of NDA to and communication from FDA will both occur in H2 of 2017​.  Full Article

UCB and Dermira announce US and EU regulatory submissions for Cimzia
Tuesday, 25 Jul 2017 01:15am EDT 

July 25 (Reuters) - UCB SA ::UCB AND DERMIRA ANNOUNCE U.S. AND EU REGULATORY SUBMISSIONS FOR CIMZIA (CERTOLIZUMAB PEGOL) FOR THE TREATMENT OF MODERATE-TO-SEVERE CHRONIC PLAQUE PSORIASIS.  Full Article

Dermira prices offering of $250 million of 3 pct convertible senior notes
Wednesday, 10 May 2017 09:33pm EDT 

May 10 (Reuters) - Dermira Inc :Dermira prices offering of $250 million of 3.00% convertible senior notes.Pricing of its offering of $250,000,000 aggregate principal amount of 3.00% convertible senior notes due 2022.Notes will be senior, unsecured obligations of Dermira, and interest of 3.00% per year will be payable semi-annually in arrears.  Full Article

Dermira announces proposed offering of $250 mln of convertible senior notes
Tuesday, 9 May 2017 04:01pm EDT 

May 9 (Reuters) - Dermira Inc :Dermira announces proposed offering of $250 million of convertible senior notes.Dermira - Intends to offer, subject to market conditions and other factors, $250 million aggregate principal amount of convertible senior notes due 2022.  Full Article

Dermira qtrly net loss per share, basic, diluted $ 0.79
Monday, 8 May 2017 04:09pm EDT 

May 8 (Reuters) - Dermira Inc ::Dermira reports first quarter 2017 financial results and provides corporate update.Dermira Inc - qtrly net loss per share, basic and diluted $ 0.79.Q1 earnings per share view $-0.89 -- Thomson Reuters I/B/E/S.  Full Article

Dermira prices $168.5 mln public offering of common stock
Wednesday, 1 Mar 2017 07:47pm EST 

Dermira Inc : Dermira prices $168.5 million public offering of common stock .Dermira Inc - announced pricing of its underwritten public offering of 5,000,000 shares of its common stock at a price to public of $33.70 per share.  Full Article

BRIEF-Dermira posts Q3 loss $4.30/shr, says FDA accepts NDA for glycopyrronium tosylate

* Dermira reports third quarter 2017 financial results and announces that FDA accepts new drug application for glycopyrronium tosylate for the treatment of patients with primary axillary hyperhidrosis